1991
A Phase II Trial of Cyclosporin A in the Treatment of Refractory Metastatic Colorectal Cancer
Murren J, Ganpule S, Sarris A, Durivage H, Davis C, Makuch R, Handschumacher R, Marsh J. A Phase II Trial of Cyclosporin A in the Treatment of Refractory Metastatic Colorectal Cancer. American Journal Of Clinical Oncology 1991, 14: 208-217. PMID: 2031507, DOI: 10.1097/00000421-199106000-00007.Peer-Reviewed Original ResearchConceptsPhase II trialCyclosporin AII trialColorectal cancerEuropean Cooperative Oncology Group performance statusRefractory metastatic colorectal cancerSignificant toxicityRefractory colorectal cancerMetastatic colorectal cancerFlu-like symptomsMeasurable diseaseStable diseaseStarting doseColorectal malignancyObjective responsePerformance statusImmunosuppressive agentsInitial doseDose reductionColon cancerPatientsHuman neoplasmsExperimental modelCancerDose
1982
Dose-response curves for predicting misonidazole-induced peripheral neuropathy.
Schwade J, Makuch R, Strong J, Glatstein E. Dose-response curves for predicting misonidazole-induced peripheral neuropathy. Journal Of The National Cancer Institute 1982, 66: 1743-50. PMID: 6288238.Peer-Reviewed Original ResearchConceptsPeripheral neuropathyLinear logistic regression analysisTotal cumulative doseLogistic regression analysisLogistic regression modelsDose-response curveCumulative AUCCumulative dosePlasma eliminationPlasma concentrationsNeuropathyLinear logistic regression modelPharmacokinetic parametersPharmacokinetic curveCancer treatmentToxic agentsRegression analysisAUCRegression modelsPatientsPharmacokineticsDoseMisonidazole
1978
Thymosin in cancer patients: in vitro effects and correlations with clinical response to thymosin immunotherapy.
Chretien P, Lipson S, Makuch R, Kenady D, Cohen M, Minna J. Thymosin in cancer patients: in vitro effects and correlations with clinical response to thymosin immunotherapy. Journal Of The National Cancer Institute 1978, 62: 1787-90. PMID: 215307.Peer-Reviewed Original Research